 Consistent and compelling clinical data across rare hematological diseases support five ongoing pivotal trials in thalassemia, sickle cell disease and pediatric pyruvate kinase PK deficiency Driving toward two additional PYRUKYND indications, with potential FDA approvals in thalassemia in 2025 and sickle cell disease in 2026 Strong cash position expected to ... The post Agios Unveils 2023-2026 Value-driving Catalysts Enabling Companys Vision to Transform Patient Outcomes in Rare Di... 